Back to All Events

Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee

On Tuesday, May 22, 2018, the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and the Drug Safety and Risk Management (DSRM) Advisory Committee voted not to recommend approval of buprenorphine sublingual spray (trade name Buvaya). The vote was 1-Yes to 18-No, with no abstentions